

# Low-dose alteplase no better for acute ischemic stroke

October 3 2017

---



(HealthDay)—For key demographic subgroups of patients with acute

ischemic stroke (AIS), low-dose alteplase does not differ from standard-dose alteplase in terms of treatment effects on death or disability, according to a study published online Oct. 2 in *JAMA Neurology*.

Xia Wang, Ph.D., from the University of New South Wales in Australia, and colleagues conducted a prespecified secondary analysis of the international Enhanced Control of Hypertension and Thrombolysis Stroke Study clinical trial of low- versus standard-dose intravenous alteplase for [patients](#) with AIS. A total of 3,310 patients with a clinical diagnosis of AIS, confirmed by brain imaging, were included in the alteplase-dose arms; participants were randomized to receive low- or standard-dose alteplase. A total of 3,297 patients were included in the analysis.

The researchers found that there were no significant differences between low- and standard-dose alteplase in the [treatment effects](#) for poor outcomes (death or disability) by age, ethnicity, or severity (all  $P > 0.37$  for interaction). The [treatment](#) effects of low- versus standard-dose alteplase on functional outcome was consistent for Asians and non-Asians ( $P = 0.32$  for interaction). The reductions in rates of symptomatic intracerebral hemorrhage were generally consistent with low-dose alteplase, although the reduction was not significant by age, ethnicity, or severity.

"Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

**More information:** [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Low-dose alteplase no better for acute ischemic stroke (2017, October 3) retrieved 2 May 2024 from <https://medicalxpress.com/news/2017-10-low-dose-alteplase-acute-ischemic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.